Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP701 (Apurano Pharmaceuticals GmbH, 560ed5)
- Development stage
- Unknown
- Lead developer
- Apurano Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oromucosal
01
Overview
AP701 is an oromucosal cannabinoid spray developed by CannaXan GmbH and manufactured by Apurano Pharmaceuticals. It consists of a lipid-based nanoparticulate formulation of whole decarboxylated *Cannabis sativa L.* flowers (Bedrocan variety), standardized to 2.2 mg/mL of Δ-9-tetrahydrocannabinol (THC) and less than 0.15 mg/mL of cannabidiol (CBD). The formulation includes the full spectrum of cannabis constituents, including terpenes and flavonoids, solubilized in an aqueous preparation to enhance bioavailability. AP701 is being investigated for the treatment of chronic pain and multiple sclerosis, with Phase I trials demonstrating improved pharmacokinetic profiles compared to existing cannabinoid medications. It is chemically identical to the magistral formulation CannaXan 701-1.1 available in Germany and Austria.
- Other names
- CannaXan 701-1.1CannaXan701-1.1CannaXan-701-1.1
02
Targets
CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)
Beyond the preview
Go deeper on AP701 (Apurano Pharmaceuticals GmbH, 560ed5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP701 (Apurano Pharmaceuticals GmbH, 560ed5).